Lexology October 16, 2024
- Recent drug pricing developments underscore that the focus on drug pricing issues is likely to continue regardless of the outcome of the upcoming November elections.
- CMS recently released final guidance on the Medicare Drug Price Negotiation Program and issued a Request for Information on a proposed Medicare $2 Drug List Model for comment.
- CBO released an analysis of drug pricing policy proposals, affirming that while potential budgetary impacts of such proposals may have changed post-IRA, the implications for research and development of new drugs for patients very much remains a consideration.
- CBO has also analyzed the potential federal budgetary impact of authorizing Medicare to cover anti-obesity medications and an issue that continues to percolate in Congress.
- Stakeholders will watch...
Today's Sponsors
Today's Sponsor